fbpx

Nyheder

Lundbeckfonden Ventures nyheder

Lund, Sweden, 08.00 am CET, 18 July 2019 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone voids will publish its Q2 2019 Interim Report on 25 July 2019 at 08:00 am CET. The Company will hold a conference call and an online presentation on the same day at 13.00 CET. The...
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Cambridge, UK and Indianapolis, US –  18 July 2019: Acacia Pharma Group plc (“Acacia Pharma”, the “Company”, the “Group”), (EURONEXT: ACPH), a pharmaceutical company developing and commercialising hospital products for US and international markets, announces that its...
Type C Meeting confirmed that FDA does not believe additional clinical safety, efficacy, or pharmacology studies will be required to support NDA resubmission and review FDA confirmed that the resubmission would be under the current NDA Company accelerates timeline and now expects resubmission of FUROSCIX NDA with the FDA by mid-year 2020 BURLINGTON, Mass., July...
Cambridge, UK and Indianapolis, US – 12 July 2019: Acacia Pharma Group plc (“Acacia Pharma”, the “Company”) (EURONEXT: ACPH) welcomes an editorial published in the leading peer-reviewed journal Anesthesia & Analgesia, accompanying the print publication of results from its positive Phase 3 clinical trial of BARHEMSYS® (intravenous amisulpride) as treatment of post-operative nausea & vomiting...
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Cambridge, UK and Indianapolis, US – 8 July 2019: Acacia Pharma Group plc (“Acacia Pharma” or “the Company”), a pharmaceutical company developing and commercialising hospital products for US and international markets, announces receipt of the official...
– Proceeds to enable progression of orphan designated lead candidate SNF472 into pivotal phase 3 trial for treatment of calciphylaxis – Round led by Spanish investor Caixa Capital Risc – Deal supported by new investors Columbus Venture Partners and Alta Life Sciences in addition to international consortium of existing shareholders Palma, Spain and San Diego,...
DURHAM, North Carolina and NESS ZIONA, Israel, June 18, 2019 /PRNewswire/ — Atox Bio, a late stage clinical company developing immunotherapies for critically ill patients, today announced the Biomedical Advanced Research and Development Authority (BARDA) has exercised the next option on a performance-based contract with for the development of Reltecimod in patients with Necrotizing Soft Tissue Infections (NSTI).  Reltecimod is...
San Diego – May 20, 2019 – Reneo Pharmaceuticals, a clinical stage pharmaceutical company, today announced that it has completed a $50 million Series A financing to develop therapies for diseases associated with deficits in cellular metabolism and energy production. The A round was led by New Enterprise Associates. Other participants in the round include Lundbeckfonden...
Today, on 14 May 2019, an annual shareholders’ meeting was held in BONESUPPORT HOLDING AB. A summary of the resolutions adopted follows below. All resolutions were adopted with the required majority. Resolution on adoption of accounts and allocation of the company’s result The annual shareholders’ meeting resolved to adopt the profit and loss statement and...
1 2 3 4 5 60

Lundbeckfonden Ventures

Nyheder

Acacia Pharma Group PLC – PDMR Dealing/Issue of Equity
1. oktober 2019
Change in number of shares and votes in BONESUPPORT HOLDING AB (publ)
30. september 2019
Acacia Pharma Group PLC – Acacia Pharma Announces New BARHEMSYS® PDUFA Target Date of 26 February 2020
26. september 2019